ALX Oncology

Our Chief Business Officer, Allison Dillon, PhD will be in Boston June 16 - 19 for the Biotechnology Innovation Organization International Convention. We look forward to connecting with you #BIO2025. #Biotech #Innovation #Pharma

ALX Oncology will attend the Jefferies 2025 Global Healthcare Conference in New York City this month. Make sure to tune into the fireside chat with our CEO, Jason Lettmann. Registration details can be found here: https://bit.ly/43AFYDv

#ICYMI: During Tuesday's R&D Day webcast, we highlighted the unique design profile, preclinical data and clinical development plans for our investigational EGFR #ADC ALX2004. Read more here: https://bit.ly/43x1V4V

Today at #AACR25, MD Anderson Cancer Center’s Paolo Strati, M.D., will present final results from the investigator-sponsored Phase 1 trial evaluating our lead investigational medicine, evorpacept, with an anti-cancer antibody treatment for patients with B-cell non-Hodgkin lymphoma. Read the release: https://bit.ly/3Yk42r2 #innovation #oncology

#NEWS: Today, we announced that the FDA has cleared the Investigational New Drug application for our company’s potential best- and first-in-class antibody-drug conjugate (ADC) that targets epidermal growth factor receptor (EGFR)-expressing solid tumors. As our first #ADC fully designed and developed in-house this is an important milestone in our mission to deliver breakthrough therapies that will help transform the future of #cancer treatment. Learn more: https://lnkd.in/edt7khNM #FDAApproval #IND #Oncology #Biotech

At ALX Oncology we’re committed to delivering highly differentiated, breakthrough therapies that transform the future of cancer treatment.      Our CEO Jason Lettmann recently spoke with Biocom California to discuss how ALX’s synergistic approach to cancer treatment has the potential to enhance patient outcomes and lessons he’s learned from leading both #biotech and #venturecapital organizations.     See the full spotlight linked below.    #MemberSpotlight #CEO #CD47 #Immunotherapy #Oncology #Cancer #innovation 

#ICYMI: During today’s R&D Day webcast, we highlighted updates on our ongoing evorpacept clinical development program, including progress of ongoing trials and introduction of new trials in breast and colorectal cancer indications, the addition of our novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, and business and financial updates. Read more here: bit.ly/4hb07Ub #Cancer #ADC #CD47 #InvestorDay

We hope you’ll join us for our virtual R&D Day on March 5 at 6am PT/ 9am ET. During this webcast we’ll discuss our #clinical program progress and our lead investigational CD47-blocker, evorpacept, and share business and financial updates. Register here: bit.ly/3Qox18L #CD47 #Oncology #InvestorDay

We’re excited to share the launch of our redesigned website! We’ve updated our site to include our most recent clinical and pipeline updates and corporate news, and showcase how we are working to advance therapies that boost the immune system to treat cancer and extend patients’ lives – all with a modern design and an infusion of our inventive company personality. Check it out: https://alxoncology.com/

#ICYMI: ALX Oncology’s CD47 blocker is making waves with promising, updated Phase 2 data in HER2-positive gastric and gastroesophageal junction (GEJ) cancer. Check out a recent article in Scrip that highlights how our investigational therapy has now become the only CD47 agent to demonstrate both durable improvement in overall response rate and a well-tolerated safety profile in a prospective randomized study. Kohei Shitara, M.D., presented the updated data from ALX Oncology’s Phase 2 ASPEN-06 trial at #ASCO #GI25. Read more: https://bit.ly/42NOtLi #Oncology #Immunotherapy #GastricCancer #Biotech #Cancer #ClinicalTrial